Humans are living longer, healthier and better lives than ever before in history. Advances in medicine, nutrition and technology are enabling life expectancies to scale to ever higher records. Children born today in the UK and in most of the developed world can easily expect to see the dawn of the 22nd century. This progress is even more accentuated in the emerging world, where health conditions are rapidly improving and converging upwards.
It’s time to learn why Healthtech is the key to manage longevity and an ageing population.
THE HEALTHCARE REVOLUTION: MANAGING HEALTHY AGEING WITH HEALTHTECH
Despite the incredible progress, advancements in digital technology, genetics and artificial intelligence (AI) are about to revolutionise healthcare in a way thought impossible even only 5 years ago. Among the most important trends are those connected to Anti-Aging, Lifestyle Management and Genomics. These 3 aspects of healthcare are in the process of powering the growth of a global health and wellness sector that has already expanded from $1.9 TLN in 2009 to more than $3.7 TLN in 2015.
It is therefore not surprising that the global leaders of the technology sector are looking to expand their presence in digital health. Apple and Google have already made their mark by introducing innovations such as Google Fit and Apple HealthKit, merging the diagnostic capabilities of mobile devices with health data collection and analysis.
“We can’t think of anything more significant than this.” – Apple COO Jeff Williams on the impact of digital technology on healthcare
A string of healthtech acquisitions by both companies has further confirmed their long-term commitment to the sector.
What are the origins of this strong and growing interest?
HEALTHTECH, DIGITAL LIFESTYLE MANAGEMENT & PRECISION GENOMICS: THE KEYS TO HUMAN LONGEVITY
Joseph Coughlin, founder and director of the MIT AgeLab, coined the term “Longevity Economy” to describe the economic activity by the over-50 population in the USA and globally. This economic opportunity is almost unrivalled in scale and scope, with a potential to reach $13.2 trillion by 2032.
Part of this growth is a result of changing attitudes towards how healthcare and medicine are administered. Governments and healthcare institutions increasingly consider the future of healthcare not to be treatment via pharmaceuticals, but rather customised disease prevention based on an individual’s genetics, lifestyle and environment.
The importance of nutrition and lifestyle management in determining quality and length of life is becoming an undisputed fact. Studies conducted by the WHO, OECD, CDC and the world’s top universities (including Harvard, MIT and Stanford) show how lifestyle changes correlate strongly to increases in the quality and length of life.
In addition, advances in genomics have shown how the interaction of genetic makeup with environmental conditions is of pre-eminent importance in determining longevity. The study of this interaction has enormously boosted the understanding of how hereditary conditions in cancer, cardiology, neuromuscular and other diseases develop. Consequently, scientists are now in the position to more effectively counter the progression of aging and better prevent age-related diseases.
MOBILE HEALTH AND LONGEVITY MANAGEMENT
Mobile health technology (mHealth) is the final and fundamental component of the Longevity Economy. Apps can help monitor on a continuous basis an individual’s eating, sleeping, exercise and work habits, tweaking them in real-time to maximise health, disease prevention and longevity. The boom in the number of health apps available and that are being downloaded (over 3.2 billion in 2016 alone), point to a global population ready to become a fundamental participant in the management of its own health.
What has been missing, to date, was a product that could incorporate genomics, lifestyle management and digital technology – in one solution. A solution that would enable anyone to record health statistics with a mobile app and simultaneously provide tailor-made diet, skincare, lifestyle and fitness planning. This solution is now finally here thanks to Suisse Life Science Group.
THE SUISSE LIFE SCIENCE SOLUTION: ARTIFICIAL INTELLIGENCE AT THE SERVICE OF AGEING PREVENTION
Suisse Life Science Group (SLSG) has positioned itself at the crossroads of AI, genomics and lifestyle management. The company’s My iDDNA® has been hailed as a pioneer invention in digital health, an AI-based digital concierge that provides holistic solutions centred on the user’s genetic biomarkers. The My iDDNA® mobile app monitors in real-time vital statistics, pollution and environmental conditions, in addition to the user’s daily food consumption and physical activity patterns.
Each user benefits from a personal genomic map, based on which My iDDNA® provides skincare treatments and nutritional supplement plans customised to the user’s genetic profile. My iDDNA® therefore combines genetics, lifestyle and environment to plan for all healthcare-related aspects, including:
- Optimising sleep patterns
- Managing fitness activity to maximise performance and well-being
- Hairloss prevention
- Fostering hormonal balance
- Preventing genetic and hereditary diseases
- Improving sexual desire and performance
- Increasing fertility
- Providing skincare solutions customised to the user’s DNA profile
- Boosting mental activity, memory and focus
And many others. My iDDNA® is a 100%-personalised AI health and wellness solution that has undergone a rigorous R & D process since 2008 before its pre-market launch in 2014. My iDDNA® is launching in the UK in November 2017 with plans for further countries in the works. UK investors have now the unique opportunity to invest in SLSG and profit from the future of age management, mobile health and personalised wellness.
INVESTING IN DIGITAL HEALTH WITH THE ENTERPRISE INVESTMENT SCHEME (EIS)
In 2017 SLSG was approved for the UK’s Enterprise Investment Scheme (EIS). The EIS is designed to help the UK’s most innovative startups raise money while providing advantageous tax benefits to investors. EIS investors can claim a 30% income tax relief on up to £1 million, if the shares are held for at least 3 years. There is no minimum investment and no capital gains tax. after shares are sold. Losses can also be deducted from the individual’s income tax obligation for the year. More than 26,000 companies have gone through the scheme since 1993, raising more than £15.6 BLN in funds.
Thanks for reading 🙂 If you enjoyed this article, press the social media button to share it. Would mean a lot to us and will help other people see the story.